Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK/Exelixis: The End of an Era

This article was originally published in The Pink Sheet Daily

Executive Summary

Six-year alliance allowed Exelixis to build a pipeline; after gaining $260 million in funding, GSK walks away with rights to only one compound.

Related Content

Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal
Exelixis Hopes To Avoid The Whole Capital Mess By Peddling Its Pipeline
GSK Taps Cellzome For Inflammatory Disease Deal
Regulus Signs Potential $600 Million MicroRNA Collaboration With GSK
GSK Selects Exelixis’ Phase II MET Inhibitor XL880
GSK Selects Exelixis’ Phase II MET Inhibitor XL880
Novartis Looks To Bring First-In-Class Vascular Disrupting Agent To Market





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts